Thus, future studies should focus on evaluating the efficacy of DGAT1 inhibition alone, or in combination with inhibition of anti-ROS mechanisms, to induce the most well-tolerated and beneficial outcomes for cancer patients. The gene discussed is DGAT1; the disease is cancer.